GBP1 Antibodies

Guanylate-binding protein 1 (GBP1)

Hydrolyzes GTP to GMP in 2 consecutive cleavage reactions. Exhibits antiviral activity against influenza virus.

Promote oxidative killing and deliver antimicrobial peptides into autophagolysosomes, providing broad host protection against different pathogen classes. .

Gene Information

Human
Gene Name:	GBP1
Uniprot:	P32455
Entrez:	2633

Family

Belongs to:
TRAFAC class dynamin-like GTPase superfamily

Alternative Names

GBP-1; GTP-binding protein 1; Guanine nucleotide-binding protein 1; guanylate binding protein 1, interferon-inducible; guanylate binding protein 1, interferon-inducible, 67kDa; huGBP-1; interferon-induced guanylate-binding protein 1

Molecular Weight

Mass (kDA):
67.931 kDA

Genomic Context

Human
Location:	1p22.2
Sequence:	1; NC_000001.11 (89052319..89065208, complement)

Subcellular Localizations

Cytoplasm. Golgi apparatus membrane; Lipid-anchor; Cytoplasmic side. Cell membrane. Secreted. Secreted from endothelial cells in the cerebrospinal fluid, upon bacterial challenge and independently of IFNG induction. Golgi membrane localization requires isoprenylation and the presence of another IFNG-induced factor.

Diseases

• Inflammation
• Neoplasms
• Tumor Angiogenesis
• Malignant Neoplasms
• Glioma
• Pathologic Neovascularization
• Adenocarcinoma
• Carcinoma
• Virus Diseases
• Cell Invasion
• Glioblastoma
• Vesicular Stomatitis
• Stomatitis

• Hypoxia
• Sarcoma
• Influenza
• Hepatitis
• Prostatic Neoplasms
• Malignant Neoplasm Of Ovary
• Colorectal Cancer

Pathways

• Angiogenesis
• Cell Proliferation
• Localization
• Immune Response
• Endothelial Cell Proliferation
• Cell Death
• Transport
• Response To Interferon-gamma
• Cell Growth
• Pathogenesis
• Cell Migration
• Virulence
• Myelination

• Chemotaxis
• Glucose Transport
• Prenylation
• Macrophage Activation
• Drug Resistance
• Cellular Localization
• Secretion

PTMs

• Phosphorylation
• Prenylation
• Farnesylation

• Biotinylation
• Sumoylation
• Cleavage

• Acetylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/GBP1

Best Uses Of The GBP1 Marker

You've found the right place if you are looking for a primary anti-globulin antibody to GBP1. Boster provides high-affinity primary antibodies that have been validated for use in ELISA, Immunohistochemistry, and Western Blotting. Continue reading for more information. Below are some things you should remember before buying an antibody. Boster antibodies are rigorously tested and have high citation rates in the research community.

Anti-GBP1

Anti-GBP1 BosterBio antibody reacts in Human, GBP1(guanylate-binding proteins) and has been tested for Western Blot (WB). The antibody is made with 5mg BSA. It contains the full length protein (566-89aa). The manufacturer offers a variety of blocking peptides to suit different lengths. This product can be used in both ELISA- and IHC applications.

Boster Bio is an antibody manufacturer with a portfolio of over 12,000 antibodies that have been validated for use in ELISA and IHC assays. Its antibodies are tested quantitatively against a panel of 250 tissue samples and untransfected cell lines, and feature high affinity and specificity. The Boster Anti-GBP1 Boster Bio antibody is a good choice for your next project. Its excellent quality and competitive pricing will make you the winner in your research.

Anti-GBP2

Steven Boster (inventor of PicoKine ELISA Platform) discovered the GBP1 mark in 1993. He developed his first product. He created many other products for IHC and hundreds more primary antibodies. He was China’s largest manufacturer of antibodies by the end the 90s. The company grew to become a global brand, and developed its own proprietary ELISA platform, PicoKine(tm). It also uses proprietary trade secret to deliver highly sensitive ELISA Kits.

The gene's expression has been detected in hBMMSCs at different stages of osteogenic differentiation. GBP1 is necessary for osteogenic differentiation in MSCs. GBP1 is required for IDO expression, which is a key signal to osteoblasts. Knockdown of GBP1 inhibits osteogenic differentiation of hBM-MSCs, although it partially rescues their osteogenic potential.

Anti-GBP3

The current study shows that osteogenic differentiation is suppressed by overexpression of GBP1 within hBM-MSCs. This is shown by western blot, RTPCR, and western blot. We also found that GBP1 expression is inhibited by overexpression after osteogenic induction for 7 days.

In the knockdown experiment, we found that GBP1 inhibits ostegenesis by regulating IFN–g signaling. This observation is in line our previous studies which indicated that GBP1 may inhibit the osteogenesis of MSCs through blocking the activity IFN-g. For these and other purposes, GBP1 is an excellent candidate for clinical trials.

During osteogenic differentiation of hBM-MSCs, GBP1 expression decreased while GBP2 expression increased. GBP3 & GBP4 remained unchanged during osteogenic differentiate. The following sections discuss the best uses for the GBP1 marker in bone growth and development. The results are marked by asterisks to indicate a statistically significant difference from baseline.

Anti-GBP4

GBP1 is a member in the SQSTM1 group of secreted protein families. It is responsible for promoting the production of bacteriolytic and other peptides. The gene also helps produce IFNgamma, a protein which promotes host defense against bacterial infected. Its best uses, like most of SQSTM1 subunits are unknown.

Anti-GBP5

Boster Bio is the right place to go if you are looking for the best antibody that detects GBP1. Boster Bio produces antibodies which are highly specific and remarkably sensitive, making them a top choice for research. If you are working with a particular immunogen length, blocking peptides can be purchased. This article will provide a brief overview on how to use Boster antibody.

The first study found that siRNA-mediated knockdown of GBP1 enhanced osteogenic differentiation of human BM-MSCs. RT-PCR results confirmed that knockdown of GBP1 enhanced ALP staining and ALP activity in hBM-MSCs after seven days of osteogenic differentiation. GBP1 knockdown promoted osteogenic distinction in hBM/MSCs. Ectopic expression of the marker reduced the osteogenic potential of the hBM/MSCs.